Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
STTK vs ATYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ATYR Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 2–4 Matrix Metrics)
ATYR Overall Winner
6-Pillar Tally: STTK 1 – 3 ATYR (2 Tie)
Matrix Metrics: STTK 4 – 2 ATYR
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Shattuck Labs, Inc. (STTK) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). STTK carries a Unified Composite Score of 52.1/100 (HOLD) at $4.55 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While STTK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (2–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -66.6% YoY).
- Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.6); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About STTK vs ATYR
STTK
Shattuck Labs, Inc. Common Stock
$4.55
-2.25% 1D
Market Cap
$473.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.46β · 76% Vol
Unified Composite Score
52.1
HOLD
Tech 57.0
Fund 57.0
Flow 63.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
ATYR
Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
$4.83
-7.82% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.57β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (STTK 1 – 3 ATYR)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
ATYR
Revenue Growth (YoY)
-66.6%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
N/A
Market Cap
$473.6M
$15.6M
3. Profitability & Quality
STTK
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-47.2%
-93.7%
4. Balance Sheet & Cash Flow
ATYR
Cash Generation (TTM)
-$50M
N/A
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$59M Net Cash
$4.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ATYR
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
72.4% (10th %ile)
154.5% (36th %ile)
Put/Call OI Skew
4.54x (Put-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: STTK (4) vs ATYR (2)| Institutional Metric | STTK | ATYR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $473.6M | $15.6M | STTK | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -66.6% | +0.0% | ATYR | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -47.2% | -93.7% | STTK | |
| 52-Week Range Position | 43% ($2–$8) | 60% ($0–$8) | ATYR | |
| Beta / 30D Volatility | 1.46β · 76% Vol | -9.57β · 13806% Vol | STTK | |
| Unified Institutional Score | 52.1 / 100 (HOLD) | 34.3 / 100 (SELL) | STTK | |
| Trailing 12M Revenue (USD) | N/A | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$50M ($59M Net Cash) | N/A ($4.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +2728.23 pp
3M Horizon
ATYR +847.07 pp
6M Horizon
ATYR +921.33 pp
1Y Horizon
ATYR +399.14 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | STTK Revenue | ATYR Revenue | STTK Op. Margin | ATYR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $0M | -253.5% | -5445.0% | STTK |
| FY2020 | $10M | $10M | -371.8% | -152.2% | ATYR |
| FY2021 | $30M | N/A | -150.8% | N/A | STTK |
| FY2022 | $0M | $10M | -15848.0% | -446.8% | ATYR |
| FY2023 | $0M | $0M | -5549.6% | -15557.8% | STTK |
| FY2024 | $10M | $0M | -1408.3% | -28899.6% | STTK |
| FY2025 | $0M | $0M | -5150.8% | -40856.3% | STTK |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
STTK
BREAKDOWN
Current IV
72.4%
IV Percentile
10th %ile
Put/Call OI Skew
4.54x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
STTK Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ STTK vs ATYR Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Shattuck Labs, Inc. (STTK) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). STTK carries a Unified Composite Score of 52.1/100 (HOLD) at $4.55 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While STTK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (2–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -66.6% YoY). Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.6); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ATYR leads the Growth & Scale pillar: STTK posts -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), STTK cumulative revenue shifted +0.0% while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, STTK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.
STTK and ATYR trade at balanced relative valuation multiples. STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STTK (-47.2% ROE) versus ATYR (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.54x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 76% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ATYR vs STTK · Reverse Pair
STTK vs PRLD
· Sector Peer
STTK vs TSHA
· Sector Peer
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma